Feeds:
Posts
Comments

Archive for the ‘Bone loss’ Category

URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>

Read Full Post »

BETTER HEALTH RESEARCH: Prostate cancer patients may be at an increased risk of suffering from bone mineral content loss compared to men who are cancer-free. READ MORE>

Read Full Post »

REUTERS: The US Food and Drug Administration has approved the sale of Amgen Inc’s osteoporosis drug Prolia – denosumab – to help prevent fractures in advanced cancer patients just days after the medicine received European approval. It will cost $US825 per 60 milligram injection. READ MORE>

Read Full Post »

URO TODAY: Patients undergoing three dimensional external beam radiation therapy for prostate cancer may be at an increased risk of hip fracture and could benefit from additional measures to improve bone health following treatment. READ MORE>

Read Full Post »

NEW PROSTATE CANCER INFO-LINK: A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. READ MORE>

Read Full Post »

URO TODAY: A fracture-reducing drug called toremifene has a useful side effect when used on prostate cancer patients – it significantly reduces hot flushes caused by hormone therapy. READ MORE>

Read Full Post »

URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>

Read Full Post »

NORWAY POST: Alpharadin, a new drug that treats men with hormone-refractory prostate cancer that has spread to the bone, will be developed by a Norwegian cancer therapeutics company and global drugs giant Bayer. READ MORE>

Read Full Post »

CANCER CONSULTANTS.COM: A drug treatment called Bonefos (sodium clodronate) – that blocks the function of the cells which reabsorb bone – reduces the risk of death by 23% in men with metastatic prostate cancer, report UK researchers. READ MORE>

Read Full Post »

CANCER CONSULTANTS: Clodronate reduces the risk of death by 23% in men with metastatic prostate cancer, according to the results of a study published in The Lancet Oncology. Clodronate belongs to a class of drugs called bisphosphonates, which are used to treat or prevent bone complications. READ MORE>

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 26 other followers